Skip to main content
. 2022 Oct 6;14(19):4148. doi: 10.3390/nu14194148

Table 5.

Evidence levels in support of the suggestion not to carry out the measurement of serum values of 25 (OH) D in the specific categories of subjects/patients described here.

Evidence Levels
We suggest that baseline levels of 25(OH)D should not be routinely assessed in patient candidates for pharmacological treatment for osteoporosis or other metabolic bone disorders (that are mandatorily associated with vitamin D supplementation), unless osteomalacia is suspected. ⊕⊕